Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2020 Nov;27(12):4637-4642. doi: 10.1245/s10434-020-08886-9. Epub 2020 Jul 30.
Whether routinely prescribed opioids are necessary for pain control after discharge among lumpectomy/sentinel node biopsy (Lump/SLNB) patients is unclear. We hypothesize that Lump/SLNB patients could be discharged without opioids, with a failure rate < 10%. This study prospectively examines outcomes after changing standard discharge prescription from an opioid/non-steroidal anti-inflammatory drug (NSAID) to NSAID/acetaminophen.
Standard discharge pain medication orders included opioids in the first 3-month study period and were changed to NSAID/acetaminophen in the second 3-month period. Patient-reported medication consumption and pain scores were collected by post-discharge survey. Frequency of discharge with opioid, NSAID/acetaminophen failure rate, opioid use, and pain scores were examined.
From May to October 2019, 663 patients had Lump/SLNB: 371 in the opioid study period and 292 in the NSAID period. In the opioid period, 92% (342/371) of patients were prescribed an opioid at discharge; of 142 patients who documented opioid use on the survey, 86 (61%) used zero tablets. Among 56 (39%) patients who used opioids, the median number taken by POD 5 was 4. After the change to NSAID/acetaminophen, rates of opioid prescription decreased to 14% (41/292). The NSAID/acetaminophen failure rate was 2% (5/251). Among survey respondents, there was no significant difference in the maximum reported pain scores (POD 1-5) between the opioid period and the NSAID period (p = 0.7).
In Lump/SLNB patients, a change to default discharge with NSAID/acetaminophen resulted in a 78% absolute reduction in opioid prescription, with a failure rate of 2% and no difference in patient-reported pain scores. Most Lump/SLNB patients can be discharged with NSAID/acetaminophen.
在接受保乳术/前哨淋巴结活检(Lump/SLNB)的患者中,是否常规开具阿片类药物来控制出院后的疼痛尚不清楚。我们假设,Lump/SLNB 患者可以在不使用阿片类药物的情况下出院,失败率<10%。本研究前瞻性地检查了从阿片类药物/非甾体抗炎药(NSAID)标准出院处方改为 NSAID/对乙酰氨基酚后的结果。
标准出院疼痛药物医嘱在研究的前 3 个月包括阿片类药物,在随后的 3 个月改为 NSAID/对乙酰氨基酚。通过出院后调查收集患者报告的药物使用情况和疼痛评分。检查出院时使用阿片类药物、NSAID/对乙酰氨基酚失败率、阿片类药物使用情况和疼痛评分。
2019 年 5 月至 10 月期间,共有 663 例患者接受了 Lump/SLNB 治疗:阿片类药物研究期间 371 例,NSAID 期间 292 例。在阿片类药物治疗期间,92%(342/371)的患者出院时开具了阿片类药物;在接受调查的 142 例使用阿片类药物的患者中,86 例(61%)使用了零片。在 56 例(39%)使用阿片类药物的患者中,POD5 时中位数服用的药物数量为 4 片。改为 NSAID/对乙酰氨基酚后,阿片类药物处方率降至 14%(41/292)。NSAID/对乙酰氨基酚的失败率为 2%(5/251)。在接受调查的患者中,阿片类药物治疗期和 NSAID 治疗期的最大报告疼痛评分(POD1-5)之间无显著差异(p=0.7)。
在接受 Lump/SLNB 治疗的患者中,将默认出院药物改为 NSAID/对乙酰氨基酚可使阿片类药物处方的绝对减少 78%,失败率为 2%,患者报告的疼痛评分无差异。大多数 Lump/SLNB 患者可以出院时使用 NSAID/对乙酰氨基酚。